Equities researchers at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a note issued to investors on Monday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright decreased their target price on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th.
Get Our Latest Stock Report on DBV Technologies
DBV Technologies Price Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. The company had revenue of $1.41 million during the quarter, compared to analysts’ expectations of $3.20 million. As a group, research analysts expect that DBV Technologies will post -1.22 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
- Five stocks we like better than DBV Technologies
- Top Biotech Stocks: Exploring Innovation Opportunities
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Best Stocks Under $10.00
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.